An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)

Trial Profile

An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Romidepsin (Primary) ; Dexamethasone
  • Indications Hodgkin's disease; Multiple myeloma; T cell lymphoma
  • Focus Therapeutic Use
  • Acronyms RID
  • Most Recent Events

    • 29 Sep 2016 Status changed from recruiting to discontinued.
    • 10 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top